Investments
6Portfolio Exits
3About Michael Berman
Michael Berman is a medical device investor/entrepreneur who serves on the boards of 9 emerging medical device companies. Mr. Berman was a co-founder of Velocimed which was sold to St. Jude Medical in April, 2005. From 1995-2000 Mr. Berman was the President of the Cardiology business of Boston Scientific. About Michael's education, He's completed a BS from Cornell University in 1979and MBA from Cornell University in 1986.
Michael Berman Headquarter Location
10727 Genevieve Lane
Minnetonka, Minnesota, 55305,
United States
Latest Michael Berman News
Jan 7, 2022
In an expansion of its current leadership team, M&T Realty Capital Corporation (M&T RCC) today announced that Michael Edelman, previously Group Vice President, has been named President of the organization. In this new role, Edelman will report directly to M&T RCC CEO, Michael Berman, and will be responsible for external customer and capital relationships, including continuing his previous work leading the organization’s relationships with Fannie Mae and Freddie Mac. Edelman, a 6-year veteran of M&T RCC, will also focus on growing the FHA and the Life Co-Placement platforms as well as enhancing M&T RCC’s integration with M&T Bank. “Mike has been a key player in the lending arena for over 25 years, and we welcome his increased leadership role at M&T RCC,” said Berman. “I look forward to collaborating with Mike and our Chief Operating Officer, Christine Chandler, as the three of us and our team continue to grow our lending and servicing enterprise with the highest standards of excellence.” Prior to joining M&T, Edelman held various roles at Freddie Mac in NYC, and ultimately served as Vice President managing Freddie Mac’s Northeast Region. In that role, he was responsible for lender development, managing a staff of over 25 professionals, overseeing a loan portfolio over $30 billion and annual origination volume of approximately $5 billion, including mixed-use properties, senior housing, co-ops, LIHTC and bond credit enhancements. [To share your insights with us, please write to sghosh@martechseries.com ]
Michael Berman Investments
6 Investments
Michael Berman has made 6 investments. Their latest investment was in Rebiotix as part of their Series B on August 8, 2014.
Michael Berman Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
8/4/2014 | Series B | Rebiotix | $25M | No | 2 | |
2/9/2012 | Series A | |||||
11/4/2011 | Series A | |||||
3/11/2011 | Series C - II | |||||
8/19/2009 | Series C |
Date | 8/4/2014 | 2/9/2012 | 11/4/2011 | 3/11/2011 | 8/19/2009 |
---|---|---|---|---|---|
Round | Series B | Series A | Series A | Series C - II | Series C |
Company | Rebiotix | ||||
Amount | $25M | ||||
New? | No | ||||
Co-Investors | |||||
Sources | 2 |
Michael Berman Portfolio Exits
3 Portfolio Exits
Michael Berman has 3 portfolio exits. Their latest portfolio exit was Rebiotix on April 05, 2018.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
4/5/2018 | Acquired | 3 | |||
Date | 4/5/2018 | ||
---|---|---|---|
Exit | Acquired | ||
Companies | |||
Valuation | |||
Acquirer | |||
Sources | 3 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.